CorrectSequence Therapeutics (Correctseq), a biotechnology company using innovative base editing technology to help people with severe disease, today announced that Dr. Susan Mou, CEO of Correctseq and Dr. Lijie Wang, head of Gene Editing Platform of Correctseq, will attend the 18th Academy for Sickle Cell and Thalassaemia Conference (ASCAT) at the County Hall London, UK on October 25-28, 2023. Dr. Lijie Wang, will give an oral presentation on Oct. 28, at 9:00 am - 11:15 am, local time.
Date: October 28, 2023
Time: 9:00 am - 11:15 am
Title: Development of Best-in-Class Gene Editing Therapy for β-Hemoglobinopathies Using Innovative Transformer Base Editor (tBE)
Location: County Hall, London, United Kingdom
CS-101 is an ex vivo gene editing hematopoietic stem cell therapy which uses tBE to reactivate γ-globin of hematopoietic stem cells for the treatment of β-hemoglobinopathies including β-thalassemia and sickle cell disease. Compared with Cas nuclease gene editing therapy and regular base editing therapy, tBE exhibits higher γ-globin induction, lower cytotoxicity, and undetected off-target mutations.
“We are very glad to be invited to participate in ASCAT Conference. This is our first presentation to the worldwide to introduce our base editing technologies. Thanks to the organizer of ASCAT Conference for the recognition and this opportunity.” Dr. Susan Mou, CEO of Correctseq said, “The advantages of tBE will help us to develop a potential best-in-class gene editing therapy for β-hemoglobinopathies. We have successfully scaled up the cell manufacturing process from laboratory to clinical and even commercial levels. The tBE-edited hematopoietic stem cells exhibited long-term safety and efficacy in mice for more than 6 months. In addition, CS-101 IND package is compliance with ICH, China, US, and EU regulatory guidelines. We are looking for collaboration opportunities with global partners to expand the scope of CS-101 clinical study, hopefully to benefit more patients worldwide.”
About CorrectSequence Therapeutics
CorrectSequence Therapeutics (Correctseq) aims to use our innovative base editing technology to help people with severe diseases.
We have developed multiple base editing systems and our base editors offer significant advantages in controlling off-target effects and improving in vivo editing efficiency. Our base editing studies were published in high-profile scientific journals including Nature Biotechnology, Nature Cell Biology, Nature Structural & Molecular Biology, Cell Research and Cell Reports.
Our goal is to discover, develop, manufacture, and commercialize curative genetic medicines for various diseases. Multiple pipelines for genetic diseases, cancer immunotherapy, metabolic diseases, and infectious diseases are well underway. We have set up R&D and manufacturing centers in Shanghai, as well as the regulatory and clinical center in Beijing. Our world-class R&D laboratory, CMC process development laboratory and cGMP manufacturing facility guarantee the rapid translation and application of our innovative research.
We focus on biotechnology innovation, research and development and are committed to providing efficient, reliable and safe solution for unmet medical needs.